Chronochemoprevention of Prostate Cancer

前列腺癌的时间化学预防

基本信息

  • 批准号:
    7267944
  • 负责人:
  • 金额:
    $ 17.07万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-07-01 至 2008-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Circadian rhythms are regular, self-sustained oscillations in gene expression and associated cellular functions. Many of these rhythmic changes occur over the course of a solar day. Elements of the circadian clock impact on tumor onset and/or progression, tumor therapy and drug toxicity. While there have been many preclinical and clinical studies addressing circadian timing of treatment for a wide range of established disease states, little attention has been paid to its potential impact on disease prevention. Dietary agents such as selenium and polyphenols found in green tea have chemopreventive activity for prostate cancer. This R21 application is being submitted in response to PA-04-053: Projects in Complementary Approaches to Cancer Care. It addresses how circadian timing of administration of nutritional agents can impact on prostate cancer prevention. We will use the well-characterized TRAMP mouse prostate cancer model to assess the chemopreventive effect of dosing at one of four different circadian times. These nutritional agents will be given at either 3 HALO (Hours After Light Onset), 9 HALO, 15 HALO, or 21 HALO, corresponding to the early-rest, mid-rest, early-activity, or late-activity phases of the mouse. Disease progression will be monitored by established criteria for this model, namely, histological analysis of the dorsolateral prostate (H&E, PCNA, TUNEL staining) at 16, 22, and 28 weeks and presence of lymph node and lung metastasis (by the india ink method) as well as serum assays for IGF-1 and IGFBP3 at 12 and 16 weeks of age. To assess circadian influences on the pharmacokinetics/pharmacodynamics (PK/PD) of these two agents, biodistribution studies will be performed. Radiolabeled forms of these agents are available and will be utilized to conduct these studies at the same four HALO time points that will be used in the chronopreventive therapy studies described above. These PK/PD studies will provide additional data about the absorption, uptake and clearance of these agents from prostate, blood and other tissues. Also, these studies will assess circadian influences on these parameters and will provide valuable data for correlation with the chronopreventive therapy studies. The third aim of this proposal will result in the establishment of a tissue bank consisting of residual prostate, normal tissues from critical organs, as well as blood. This will allow for future correlative studies of selected biomarkers as well as correlative genomic and proteomic studies. Overall, these proposed studies on the application of chronobiological principles, which have already been utilized successfully in cancer chemotherapy, to cancer prevention will add to the understanding of chemoprevention and hold real potential for reducing the incidence and burden of prostate cancer.
描述(由申请人提供):昼夜节律是基因表达和相关细胞功能的规则、自我维持的振荡。许多这样的节奏变化发生在一个太阳日的过程中。生物钟的要素影响肿瘤的发生和/或进展、肿瘤治疗和药物毒性。虽然已经有许多临床前和临床研究解决了广泛的疾病状态的昼夜节律治疗时机,但很少关注其对疾病预防的潜在影响。饮食剂,如硒和多酚发现在绿色茶有化学预防活性的前列腺癌。此R21申请是为了响应PA-04-053:癌症护理补充方法项目而提交的。它解决了如何昼夜节律定时管理营养剂可以影响前列腺癌的预防。我们将使用充分表征的TRAMP小鼠前列腺癌模型来评估在四个不同昼夜节律时间之一给药的化学预防作用。这些营养剂将在3 HALO(光照后小时)、9 HALO、15 HALO或21 HALO时给予,对应于小鼠的早期休息、中期休息、早期活动或晚期活动阶段。将通过该模型的既定标准监测疾病进展,即在16、22和28周时对背外侧前列腺进行组织学分析(H&E、PCNA、TUNEL染色),以及在12和16周龄时对淋巴结和肺转移的存在(通过印度墨水法)以及对IGF-1和IGFBP 3的血清测定。为了评估昼夜节律对这两种药物的药代动力学/药效学(PK/PD)的影响,将进行生物分布研究。这些药物的放射性标记形式可用,并将用于在上述时间预防治疗研究中使用的相同四个HALO时间点进行这些研究。这些PK/PD研究将提供关于这些药物从前列腺、血液和其他组织中吸收、摄取和清除的额外数据。此外,这些研究将评估昼夜节律对这些参数的影响,并将提供与时间预防治疗研究相关的有价值的数据。该提案的第三个目标是建立一个组织库,由残余前列腺、关键器官的正常组织以及血液组成。这将使未来的相关研究选定的生物标志物以及相关的基因组和蛋白质组学研究。总的来说,这些关于时间生物学原理应用的拟议研究(这些原理已经成功地用于癌症化疗)将增加对化学预防的理解,并具有降低前列腺癌发病率和负担的真实的潜力。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JACK D BURTON其他文献

JACK D BURTON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JACK D BURTON', 18)}}的其他基金

Chronochemoprevention of Prostate Cancer
前列腺癌的时间化学预防
  • 批准号:
    7141662
  • 财政年份:
    2006
  • 资助金额:
    $ 17.07万
  • 项目类别:
Chronobiological Principles to Maximize Efficacy of Alt*
最大化 Alt 功效的时间生物学原理*
  • 批准号:
    6774793
  • 财政年份:
    2003
  • 资助金额:
    $ 17.07万
  • 项目类别:
RADIOIMMUNOTHERAPY OF EXTENSIVE STAGE SCLC
广泛期SCLC的放射免疫治疗
  • 批准号:
    6173564
  • 财政年份:
    1999
  • 资助金额:
    $ 17.07万
  • 项目类别:
RADIOIMMUNOTHERAPY OF EXTENSIVE STAGE SCLC
广泛期SCLC的放射免疫治疗
  • 批准号:
    2875958
  • 财政年份:
    1999
  • 资助金额:
    $ 17.07万
  • 项目类别:
NSCLC--COMBINED CHEMOTHERAPY & RADIOIMMUNOTUNOTHERAPY
非小细胞肺癌--联合化疗
  • 批准号:
    2733406
  • 财政年份:
    1997
  • 资助金额:
    $ 17.07万
  • 项目类别:
MAB-CYTOKINE R-ALPHA FUSIONS TO DELIVER ARMED LIGAND
MAB-细胞因子 R-α 融合以提供武装配体
  • 批准号:
    2772057
  • 财政年份:
    1997
  • 资助金额:
    $ 17.07万
  • 项目类别:
NSCLC--COMBINED CHEMOTHERAPY & RADIOIMMUNOTUNOTHERAPY
非小细胞肺癌--联合化疗
  • 批准号:
    2440224
  • 财政年份:
    1997
  • 资助金额:
    $ 17.07万
  • 项目类别:
MAB-CYTOKINE R-ALPHA FUSIONS TO DELIVER ARMED LIGAND
MAB-细胞因子 R-α 融合以提供武装配体
  • 批准号:
    2452147
  • 财政年份:
    1997
  • 资助金额:
    $ 17.07万
  • 项目类别:

相似海外基金

心房細動に対するPulsed Field Ablationの組織創傷治癒過程を明らかにする網羅的研究
阐明房颤脉冲场消融组织伤口愈合过程的综合研究
  • 批准号:
    24K11201
  • 财政年份:
    2024
  • 资助金额:
    $ 17.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Targeted ablation of cerebral atherosclerosis using supramolecular self-assembly
利用超分子自组装靶向消融脑动脉粥样硬化
  • 批准号:
    24K21101
  • 财政年份:
    2024
  • 资助金额:
    $ 17.07万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
遅延造影心臓MRIによる心房細動Ablation冷却効果の比較:28 vs. 31 mm Cryoballoon
使用延迟对比增强心脏 MRI 比较房颤消融冷却效果:28 毫米与 31 毫米 Cryoballoon
  • 批准号:
    24K11281
  • 财政年份:
    2024
  • 资助金额:
    $ 17.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CAREER: Heat Penetration Depth and Direction Control with Closed-Loop Device for Precision Ablation
职业:利用闭环装置控制热穿透深度和方向,实现精确烧蚀
  • 批准号:
    2338890
  • 财政年份:
    2024
  • 资助金额:
    $ 17.07万
  • 项目类别:
    Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
  • 批准号:
    2334777
  • 财政年份:
    2024
  • 资助金额:
    $ 17.07万
  • 项目类别:
    Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
  • 批准号:
    2334775
  • 财政年份:
    2024
  • 资助金额:
    $ 17.07万
  • 项目类别:
    Continuing Grant
InSPACE-VT_Development and Validation of Virtual Pace Mapping to Guide Catheter Ablation of Ventricular Tachycardia
InSPACE-VT_虚拟起搏测绘的开发和验证以指导室性心动过速导管消融
  • 批准号:
    EP/Z001145/1
  • 财政年份:
    2024
  • 资助金额:
    $ 17.07万
  • 项目类别:
    Fellowship
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
  • 批准号:
    2334776
  • 财政年份:
    2024
  • 资助金额:
    $ 17.07万
  • 项目类别:
    Continuing Grant
MRI: Acquisition of a Laser Ablation - Inductively Coupled Plasma - Triple Quadrupole - Mass Spectrometer (LA-ICP-QQQ-MS) System For Research and Education
MRI:获取用于研究和教育的激光烧蚀 - 电感耦合等离子体 - 三重四极杆 - 质谱仪 (LA-ICP-MS/MS) 系统
  • 批准号:
    2320040
  • 财政年份:
    2023
  • 资助金额:
    $ 17.07万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了